Women in our society are judged on appearance. Overweight and obese women are downgraded in many ways, especially in relationships and jobs. These are essential areas in womens’ lives.
A recent study shows a stunning impact of GLP-1s in womens’ lives.
GLP-1–Induced Weight Loss and the Female Obesity Penalty
Rebecca Diamond, National Bureau of Economic Research, June 2026
Working Paper 35387
DOI 10.3386/w35387
Issue Date June 2026
GLP-1 medications generate large weight loss and may also alter social and economic outcomes. Using the Understanding America Study, I compare women starting GLP-1s for weight loss with matched women who would like to start a GLP-1 but have not.
Single women’s marriage/cohabitation rates rise by 29 percentage points and employment among baseline non-employed women rises 27 percentage points after six or more quarters.
Existing partnerships do not dissolve, and already-employed women show no upward job mobility. The pattern suggests that part of the female obesity penalty operates at new-match formation rather than only through health or incumbent productivity. [end quote]
“You only get one chance to make a first impression.”
When a man won’t ask a fat woman out for that first date, or when an employer won’t interview a fat woman, that woman loses the potential for her life improving.
This is a truly stunningly huge effect.
Approximately 69.4% of American adult women have overweight or obesity, according to data from the National Institute of Diabetes and Digestive and Kidney Diseases. When broken down specifically, roughly 27.5% of women are classified as overweight, and an additional 41.3% to 41.9% are classified in the obesity category.
GLP-1 drugs act on the brain’s reward center. They are psychoactive and affect the dopamine receptors.
Many users find that medication-induced regulation of the brain’s reward system can quiet obsessive thoughts about food, relieve addiction-related behaviors, and reduce anxiety and depressive symptoms.
Some patients report a general dulling of emotions or difficulty feeling joy (anhedonia). Experts suggest this might happen because the medication dampens the brain’s reward response to both food and other previously enjoyed activities.
The market for GLP-1 drugs is immense. Since their use has expanded from diabetes treatment relatively recently it’s likely that off-label uses will expand. If I was a doctor treating addiction I would try GLP-1s even in patients who aren’t overweight.
Eli Lilly and Novo Nordisk are the largest manufacturers. These are blockbuster drugs.
Wendy

